Print Page | Close Window

Cytokinetics, Inc. (NASDAQ: CYTK) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and other medical conditions.  Cytokinetics currently has three compounds in clinical development: omecamtiv mecarbil in Phase II for acute and chronic heart f Details >>

Link to Annual Report & Stockholder Meeting Materials and Information

Stock Quote
CYTK (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.45 (4.96%)
Market Cap$343,576,800
Shares Outstanding36,090,000
Data as of 04/17/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsDetails >>
04/01/14Cytokinetics to Present at the 13th Annual Needham Healthcare ConferencePrinter Friendly Version
03/28/14Cytokinetics Announces the Opening to Enrollment of the Expansion of COSMIC-HFPrinter Friendly Version
03/27/14Cytokinetics Announces Initiation of Multiple Dose Phase I Clinical Trial of CK-2127107Printer Friendly Version
02/28/14Cytokinetics to Present at Upcoming Healthcare ConferencesPrinter Friendly Version
Upcoming EventsDetails >>
There are currently no events scheduled.
Featured ReportDetails >>
Download Documentation 2010 Annual Report

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.